Jubilant Pharmova (BOM:530019) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530019 Jubilant Pharmova Ltd BOM:530019
69 GF Score
Price ₹995.45
GF Value ₹1,060.80
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Jubilant Pharmova Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BOM:530019
69GF Score
Jubilant Pharmova Ltd BOM:530019
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?

Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued. The current stock price of ₹995.45 is trading 6.2% below its estimated GF Value™ of ₹1,060.80. GuruFocus considers Jubilant Pharmova to be Fairly Valued.

Key valuation signals for BOM:530019:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ₹1,060.80 vs. price of ₹995.45 (6.2% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jubilant Pharmova Business Description

Other Exchanges JUBLPHARMA:India
Address 1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
69GF Score

Get the complete analysis for BOM:530019

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹995.45
Price
₹1,060.80
GF Value